Patents by Inventor Thomas Matthew BAKER
Thomas Matthew BAKER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230250080Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.Type: ApplicationFiled: March 27, 2023Publication date: August 10, 2023Inventors: Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Alessandro MAZZACANI, Michael John STOCKS, Thomas Matthew BAKER, Matthew Robert CONROY, Alun John SMITH, David Edward CLARK
-
Publication number: 20230183186Abstract: The present invention provides a class of pyrimidinedione cyclohekenyl compounds and methods of using these compounds as glucocorticoid receptor modulators.Type: ApplicationFiled: November 16, 2022Publication date: June 15, 2023Inventors: Hazel Hunt, Damien Francis Philippe Crepin, Joseph Thomas Hill-Cousins, Thomas Matthew Baker, Lorna Duffy
-
Patent number: 11613527Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.Type: GrantFiled: October 8, 2021Date of Patent: March 28, 2023Assignee: KalVista Pharmaceuticals LimitedInventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Alessandro Mazzacani, Michael John Stocks, Thomas Matthew Baker, Matthew Robert Conroy, Alun John Smith, David Edward Clark
-
Patent number: 11542238Abstract: The present invention provides a class of pyrimidinedione cyclohexenyl compounds and methods of using these compounds as glucocorticoid receptor modulators.Type: GrantFiled: June 3, 2019Date of Patent: January 3, 2023Assignee: Corcept Therapeutics IncorporatedInventors: Hazel Hunt, Damien Francis Philippe Crepin, Joseph Thomas Hill-Cousins, Thomas Matthew Baker, Lorna Duffy
-
Publication number: 20220289727Abstract: The present invention provides compounds of formula (I) or (Ia) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, n, R2, R3, R4, R5, and R6 are as defined herein.Type: ApplicationFiled: February 13, 2020Publication date: September 15, 2022Inventors: Mitchell Lewis CHILDS, Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Alessandro MAZZACANI, David Edward CLARK, Paul Stuart HINCHLIFFE, Thomas Matthew BAKER, Colin Peter SAMBROOK SMITH, Alun John SMITH, Joseph William WRIGGLESWORTH, Xuezheng YANG
-
Publication number: 20220048894Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.Type: ApplicationFiled: October 8, 2021Publication date: February 17, 2022Inventors: Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Alessandro MAZZACANI, Michael John STOCKS, Thomas Matthew BAKER, Matthew Robert CONROY, Alun John SMITH, David Edward CLARK
-
Publication number: 20210238148Abstract: The present invention provides a class of pyrimidinedione cyclohekenyl compounds and methods of using these compounds as glucocorticoid receptor modulators.Type: ApplicationFiled: June 3, 2019Publication date: August 5, 2021Inventors: Hazel HUNT, Damien Francis Philippe CREPIN, Joseph Thomas HILL-COUSINS, Thomas Matthew BAKER, Lorna DUFFY
-
Patent number: 10941115Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have anti-inflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: July 10, 2019Date of Patent: March 9, 2021Assignee: Oxular Acquisitions LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
-
Publication number: 20190330155Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have anti-inflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: July 10, 2019Publication date: October 31, 2019Inventors: Thomas Matthew BAKER, Matthew Colin Thor Fyfe, Geraint JONES, Stephen Malcolm THOM
-
Patent number: 10435361Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: October 5, 2017Date of Patent: October 8, 2019Assignee: Topivert Pharma LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Gareth William Harbottle, Vedran Hasimbegovic, Premji Meghani, Aaron Rigby, Colin Sambrook-Smith, Stephen Malcolm Thom
-
Patent number: 10392346Abstract: There are provided compounds of formula IIb, wherein: LG1 represents imidazolyl, chloro, or aryloxy; and Z1 represents a structural fragment of formula V: wherein R2 to R4, R5a, L and X1 to X3 have meanings given in the description, or a salt or protected derivative thereof, wherein said protected derivative is a compound in which the carboxyl moiety of R4 is protected as a C1-8 alkyl ester. The compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: July 13, 2018Date of Patent: August 27, 2019Assignee: Topivert Pharma LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
-
Patent number: 10125100Abstract: There are provided compounds of formulas III and VIIa: or a salt or protected derivative thereof, wherein Z2 represents a structural fragment of formula V, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: May 24, 2017Date of Patent: November 13, 2018Assignees: Topivert Pharma LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
-
Publication number: 20180319748Abstract: There are provided compounds of formula IIb, wherein: LG1 represents imidazolyl, chloro, or aryloxy; and Z1 represents a structural fragment of formula V: wherein R2 to R4, R5a, L and X1 to X3 have meanings given in the description, or a salt or protected derivative thereof, wherein said protected derivative is a compound in which the carboxyl moiety of R4 is protected as a C1-8 alkyl ester. The compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: July 13, 2018Publication date: November 8, 2018Inventors: Thomas Matthew BAKER, Matthew Colin Thor FYFE, Geraint JONES, Stephen Malcolm THOM
-
Publication number: 20180044288Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: October 5, 2017Publication date: February 15, 2018Inventors: Thomas Matthew BAKER, Matthew Colin Thor FYFE, Gareth William HARBOTTLE, Vedran HASIMBEGOVIC, Premji MEGHANI, Aaron RIGBY, Colin SAMBROOK-SMITH, Stephen Malcolm THOM
-
Patent number: 9890185Abstract: There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: December 19, 2014Date of Patent: February 13, 2018Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom, Thomas Matthew Baker, Gareth William Harbottle, Vedran Hasimbegovic, Aaron Rigby
-
Publication number: 20170253563Abstract: There are provided compounds of formulas III and VIIa: or a salt or protected derivative thereof, wherein Z2 represents a structural fragment of formula V, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: May 24, 2017Publication date: September 7, 2017Inventors: Thomas Matthew BAKER, Matthew Colin Thor FYFE, Geraint JONES, Stephen Malcolm THOM
-
Patent number: 9751837Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: October 1, 2015Date of Patent: September 5, 2017Assignees: RESPIVERT LIMITED, TOPIVERT PHARMA LIMITEDInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
-
Publication number: 20160318958Abstract: There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: December 19, 2014Publication date: November 3, 2016Inventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom, Thomas Matthew Baker, Gareth William Harbottle, Vedran Hasimbegovic, Aaron Rigby
-
Patent number: 9481648Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: April 1, 2014Date of Patent: November 1, 2016Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Gareth William Harbottle, Vedran Hasimbegovic, Premji Meghani, Aaron Rigby, Colin Sambrook-Smith, Stephen Malcolm Thom
-
Publication number: 20160102059Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: October 1, 2015Publication date: April 14, 2016Inventors: Thomas Matthew BAKER, Matthew Colin Thor FYFE, Geraint JONES, Stephen Malcolm THOM